EUVIMEDEUVIMED entdecken
LeitlinieOpen Access · CC BY-NC-ND 4.0

Guideline-Directed Medical Therapy for Heart Failure in Arrhythmia-Induced Cardiomyopathy with Improved Left Ventricular Ejection Fraction

Luis Manuel Domínguez-Rodríguez iD, David Dobarro, Carla Iglesias-Otero, María G Crespo-Leiro, Sergio Raposeiras-Roubín, Jesús Álvarez-García, Manuel Barreiro-Pérez, Isabel Muñoz-Pousa, Angel Sánchez-Recalde, Ándrés Íñiguez-Romo, José Luis Zamorano

European Journal of Heart Failure · 2025

DOI: 10.1002/ejhf.3556 ↗

Kurz gefasst

Leitlinie in der Zeitschrift European Journal of Heart Failure, 2025. Verfasst von Luis Manuel Domínguez-Rodríguez und 10 weiteren Autor:innen. Beteiligte Einrichtung: Cardiology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain. Hauptthemen laut MEDLINE: Stroke Volume, Heart Failure, Adrenergic beta-Antagonists, Arrhythmias, Cardiac. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

No study has analyzed the impact of guideline-directed medical therapy in preventing heart failure (HF) relapse in patients with arrhythmia-induced cardiomyopathy (AiCM) following left ventricular ejection fraction (LVEF) improvement. Methods and results We analyzed data from a single-center cohort of 200 patients admitted for HF, LVEF <50% and cardiac arrhythmia considered by cardiologists to be the precipitating cause of the episode. The primary endpoint was time-to-HF relapse, defined as the composite of readmission for HF, Emergency Department (ED) visit for HF, or significant decline in LVEF. Changes in medication were recorded and a time-varying multivariate Cox regression was performed. After a median follow-up period of 6.14 years, diagnostic confirmation was achieved in 188 out of the initial 200 patients with suspected AiCM. A total of 89 patients (47.3%) met the primary endpoint. RAS inhibitors (adjusted hazard ratio (HR) 0.50 [0.31–0.81]; p = 0.005) and beta-blockers (adjusted HR 0.48 [0.28–0.81]; p = 0.006) were associated with a lower incidence of relapse. Mineralocorticoid receptor antagonists were associated with a significantly lower incidence of ED visits for HF (adjusted HR 0.38 [0.15–0.95]; p = 0.038), but did not achieve statistical significance for the combined primary endpoint. Antiarrhythmic drugs did not show a significant impact on the primary endpoint.

Conclusion

Maintaining RAS inhibitors and beta-blockers was associated with a significantly lower incidence of relapse in the setting of AiCM with improved LVEF.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Stroke VolumeHeart FailureAdrenergic beta-AntagonistsArrhythmias, CardiacCardiomyopathiesAngiotensin-Converting Enzyme InhibitorsVentricular Function, LeftHumansMaleFemaleAgedMineralocorticoid Receptor AntagonistsMiddle AgedPractice Guidelines as TopicRetrospective StudiesFollow-Up Studies

Stichwörter der Autor:innen

Arrhythmia‐induced cardiomyopathyGuideline‐directed medical therapyHeart failureImproved ejection fractionTachycardia‐induced cardiomyopathyTachycardiomyopathy

Substanzen

Adrenergic beta-AntagonistsMineralocorticoid Receptor AntagonistsAngiotensin-Converting Enzyme Inhibitors

Autor:innen und Institutionen

  • Cardiology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain.
  • Universidad de Alcalá, Madrid, Spain.
  • Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain.
  • Cardiology Department, Hospital Universitario Álvaro Cunqueiro, Vigo, Spain.
  • Cardiology Department, Hospital Universitario de A Coruña, A Coruña, Spain.
  • Universidade de A Coruña, A Coruña, Spain.

ORCID-Profile: Luis Manuel Domínguez-Rodríguez

Zitieren

APA

Domínguez-Rodríguez, L. M., Dobarro, D., Iglesias-Otero, C., Crespo-Leiro, M. G., Raposeiras-Roubín, S., Álvarez-García, J., Barreiro-Pérez, M., Muñoz-Pousa, I., Sánchez-Recalde, A., Íñiguez-Romo, Á., & Zamorano, J. L. (2025). Guideline-Directed Medical Therapy for Heart Failure in Arrhythmia-Induced Cardiomyopathy with Improved Left Ventricular Ejection Fraction. European Journal of Heart Failure. https://doi.org/10.1002/ejhf.3556

Vancouver

Domínguez-Rodríguez LM, Dobarro D, Iglesias-Otero C, Crespo-Leiro MG, Raposeiras-Roubín S, Álvarez-García J, et al. Guideline-Directed Medical Therapy for Heart Failure in Arrhythmia-Induced Cardiomyopathy with Improved Left Ventricular Ejection Fraction. European Journal of Heart Failure. 2025. doi:10.1002/ejhf.3556

BibTeX
@article{DomnguezRodrguez2025,
  author = {Domínguez-Rodríguez, Luis Manuel and Dobarro, David and Iglesias-Otero, Carla and Crespo-Leiro, María G and Raposeiras-Roubín, Sergio and Álvarez-García, Jesús and Barreiro-Pérez, Manuel and Muñoz-Pousa, Isabel and Sánchez-Recalde, Angel and Íñiguez-Romo, Ándrés and Zamorano, José Luis},
  title = {Guideline-Directed Medical Therapy for Heart Failure in Arrhythmia-Induced Cardiomyopathy with Improved Left Ventricular Ejection Fraction},
  journal = {European Journal of Heart Failure},
  year = {2025},
  doi = {10.1002/ejhf.3556}
}
Kostenlos starten →